To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.
Aged 18-60 years, regardless of sex/gender
BMI≥28.0kg/m2
Aged 18-60 years, regardless of sex/gender
BMI≥24.0kg/m2
Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes
Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections
Use of weight-affecting products within the past three months or planned use during the study
Weight fluctuation >5 kg or >10% within the past three months